

CTAD Alzheimer 2022

Clinical Trials on Alzheimer's Disease

Preliminary program



ONSITE



ONLINE

November 29 - December 2, 2022
San Francisco, USA

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14 / Barcelona '15
San Diego '16 / Boston '17 / Barcelona '18 / San Diego '19 / Virtual '20 / Boston '21

www.ctad-alzheimer.com

Email: ctad@ant-congres.com





SUMMARY

Editorial	3
Organizing & Scientific Committees	4
Lifetime Achievement Award	5
Keynotes	6
Program at a glance	9
Onsite Program	
Tuesday, November 29	10
Wednesday, November 30	11
Thursday, December 1	14
Friday, December 2	18
Poster presentations	23

Editorial

Dear colleagues,

The field of Alzheimer's disease diagnostics and therapeutics has become one of the most exciting areas in all of medical research. The Clinical Trials on Alzheimer's Disease (CTAD) meeting, being held this **November 29-December 2, 2022**, promises to continue the excitement!

Why is our field so exciting? Rapid progress in our field has resulted from huge investments by governments into basic science research, followed by more recent huge investments by the private sector into diagnostic, biotech, and pharmaceutical companies. It has only been 15 years since molecular imaging with amyloid PET scans first demonstrated the ability to detect Alzheimer's disease pathology in living people. Now, amyloid PET is widely available, tau PET is being employed by many clinical trials, and very recently blood tests for Alzheimer's disease have shown great promise for screening, and even for diagnosis.

But, without question there is growing evidence that monoclonal antibodies, which remove amyloid plaque, appear to slow cognitive decline. Unfortunately, these treatments are also associated with ARIA, including brain swelling and bleeding in the brain. There is considerable controversy concerning the significance and impact of these findings, including whether or not governments and medical insurance will provide financial coverage for such treatments.

These issues will be at the center of the CTAD meeting being held in San Francisco this Fall. Experts from academics and industry will be attending, presenting their data and discussing the pros and cons of various controversial topics. In addition to the formal program there will be extensive networking and discussions around the poster sessions, coffee breaks, formal receptions, and in the hallways.

San Francisco is an especially beautiful city, surrounded by the Pacific Ocean and the San Francisco Bay. Golden Gate Park, and the Presidio are huge parks filled with trees, flowers and historical sites. We have three internationally famous universities, the worlds' largest biotech hub just south of the city, and Silicon Valley further south. Don't forget to include some vacation time and consider visiting the Muir Woods, the Napa Valley, and Carmel/Big Sur to the south.

I'm looking forward to seeing old friends, and making new ones at the CTAD meeting this Fall in beautiful San Francisco.

Dr. Mike Weiner
President of the CTAD22 Scientific Committee





President of the CTAD22 Scientific Committee

Michael W. WEINER, MD
University of California at San Francisco (UCSF)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Randall J. BATEMAN (St. Louis, USA); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Steven DEKOSKY (Miami, USA); Michael C. DONOHUE (San Diego, USA); Rachele DOODY (Basel, Switzerland); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FELDMAN (San Diego, USA); Nick FOX (London, UK); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Homburg, Germany); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Barcelona, Spain); Ronald PETERSEN (Minnesota, USA); Michael S. RAFII (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Las Vegas, USA); Stephen SALLOWAY (Providence, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Yong SHEN (Heife, China); Jiong SHI (Las Vegas, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Michael W. WEINER* (San Francisco, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

* Organizing Committee Member

CTAD 2022 Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Reisa Sperling MD, Ph.D. and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research.



Reisa SPERLING MD

Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, Boston, MA (USA)

Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer's disease (AD) at the pre-symptomatic or "preclinical" stage of AD. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator of the Harvard Aging Brain Study, and the NIH funded Alzheimer's Clinical Trial Consortium (ACTC). She co-leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, and recently launched two new prevention trials in the AHEAD 3-45 Study with the ACTC.



Keith JOHNSON MD

Professor of Radiology and Neurology at Harvard Medical School and Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital, Boston, MA (USA)

Dr. Johnson is a Professor of Radiology and Neurology at the Harvard Medical School. He is also an Associate Radiologist and the Director of Molecular Neuroimaging in the Division of Nuclear Medicine and Molecular Imaging at the Massachusetts General Hospital (MGH). He also serves as an associate physician and staff neurologist in the Memory Disorders Unit at the Brigham and Women's Hospital as well as a Clinical Associate in Neurology at the MGH. He is co-director of the Neuroimaging Program of the Massachusetts Alzheimer's Disease Research Center and its Dominantly Inherited Alzheimer Network (DIAN) research initiatives. He oversees the Clinical Brain Positron Emission Tomography (PET) Service at the MGH and also practices as a neurologist that specializes in neurodegenerative disorders. Dr. Johnson also maintains an Internet teaching atlas of neuroimaging known as the Whole Brain Atlas. His major research interests include the early diagnosis and treatment monitoring of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies.

Keynotes



“The Current and Future State of AD plasma biomarkers”

Kaj Blennow, MD, PhD

Academic Chair in Clinical Neurochemistry, University of Gothenburg, Head of the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Gothenburg, Sweden

Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. His main research interest is CSF and blood biomarkers for Alzheimer’s disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in clinical trials. Dr. Blennow has published more than 1700 original research papers and review articles in peer-reviewed journals, with more than 110.000 citations, and he has an H-index of 151. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer’s Association QC program for CSF and blood biomarkers.



“Targeting Immuno-Metabolic Pathways in Alzheimer’s Disease: Novel Mechanisms and Therapeutic Opportunities”

Suzanne Craft, PhD

Professor in Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Dr. Suzanne Craft received her Ph.D. from the University of Texas at Austin, and then completed fellowships at Boston University and Harvard Medical School. She has been a faculty member at Washington University in St. Louis and at the University of Washington. In 2012, she joined the faculty at Wake Forest School of Medicine, where she is Professor of Medicine, and Founding Director of the National Institute on Aging-funded Wake Forest Alzheimer’s Disease Research Center. Dr. Craft has served as a member of the Alzheimer’s Association Medical and Scientific Advisory Group, the NIA Board of Scientific Counselors, and the Executive Committee of the Alzheimer’s Clinical Trial Consortium. Dr. Craft’s research program investigates the role of metabolic disorders in the development of Alzheimer’s disease, through translational studies and innovative clinical trials of pharmacologic and dietary intervention to treat or prevent Alzheimer’s disease. She led a ground-breaking multi-site trial of intranasal insulin for the treatment of Alzheimer’s disease that was funded by the National Alzheimer’s Project Act. She has received a prestigious Zenith Award from the Alzheimer’s Association and a National Institute of Health MERIT award for research excellence. Her work has been featured in HBO’s Emmy-award winning series “The Alzheimer’s Project: Momentum in Science”, in the New York Times and Time magazine, as well as on BBC Newshour, and PBS Newshour.

Keynotes



“Precision Prevention of Dementia and Alzheimer’s Disease: Advancing Multidomain Interventions”

Miia Kivipelto, MD, PhD

Professor in Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and Director of Research and Development at Karolinska University Hospital, Stockholm (Sweden)

Miia Kivipelto is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director of Research & Development at Theme Aging and Inflammation and Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (340+ publications, H-index 78) and she has received numerous prestigious awards. Dr. Kivipelto’s translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer’s disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-



“Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer’s Disease”

Roger Nitsch, MD

CEO and President Neurimmune, Schlieren (Switzerland)

Roger Nitsch serves as CEO and President of Neurimmune, which he founded in 2006 with two business partners. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. He is a Potamkin Prize winner and Member of the German Academy of Sciences and served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich. Roger holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.



**ONSITE
PROGRAM**
in San Francisco
Available via livestream
on the CTAD22
digital platform

Program at a glance

● Tuesday, NOVEMBER 29

- 4.00 p.m. Opening Ceremony and CTAD Lifetime Achievement Award
- 4.30 p.m. **KEYNOTE 1:** Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities
- 4.50 p.m. **Lecanemab Phase 3 Topline Results**
- 6.30 p.m. CTAD Welcome Reception with the support of the Alzheimer's Association 

● Wednesday, NOVEMBER 30

- 9.00 a.m. **KEYNOTE 2:** Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions
- 9.20 a.m. **SYMPOSIUM 1:** CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials
- 10.00 a.m. Coffee break and poster session
- 10.30 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 11.00 a.m. **ORAL COMMUNICATIONS**
- 12.15 p.m. Lunch and poster sessions
- 1.20 p.m. **SYMPOSIUM 2:** Decentralization Approaches for Clinical Trials on Alzheimer's Disease
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** New Insights for Amyloid and Tau PET Imaging
- 3.00 p.m. **LATE BREAKING COMMUNICATIONS**
- 3.45 p.m. Coffee break and poster session
- 4.15 p.m. **Topline Results of Phase III GRADUATE I & II Confirmatory Trials with Subcutaneous Gantenerumab**

● Thursday, DECEMBER 1

- 9.00 a.m. **KEYNOTE 3:** The Current and Future State of AD plasma biomarkers
- 9.20 a.m. **Anti Amyloid Phase 3 results: A CTAD open discussion**
- 9.50 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Beyond Amyloid and Tau: Emerging solutions
- 10.55 a.m. Coffee break and poster session
- 11.20 a.m. **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
- 12.00 p.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 12.30 p.m. Lunch and poster sessions
- 1.30 p.m. **ORAL COMMUNICATIONS**
- 2.30 p.m. **ROUNDTABLE 1:** Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments
- 3.00 p.m. **ORAL COMMUNICATIONS**
- 4.00 p.m. Coffee break and poster session
- 4.30 p.m. **LATE BREAKING ORAL COMMUNICATIONS**

● Friday, DECEMBER 2

- 9.00 a.m. **KEYNOTE 4:** Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
- 9.20 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 10.20 a.m. Coffee break and poster session
- 10.45 a.m. **ROUNDTABLE 2:** The Alzheimer's disease Patient Pathway from a sex and gender lens
- 11.15 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Interim or preliminary data and study design
- 12.05 p.m. Lunch and poster sessions
- 1.05 p.m. **ORAL COMMUNICATIONS**
- 1.35 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION:** Clinical Trials Phase 1 Results
- 2.05 p.m. **ORAL COMMUNICATIONS**
- 3.05 p.m. Coffee break and poster session
- 3.35 p.m. **LATE BREAKING ORAL COMMUNICATION**
- 3.50 p.m. **ORAL COMMUNICATIONS**

● Tuesday,
NOVEMBER 29

- 4.00 p.m **Opening Ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research**
Presented to Reisa Sperling MD, and Keith Johnson, MD, in recognition for their outstanding contributions to the advancement of AD clinical trials research
Introduction by Paul Aisen, *Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (USA)*, Jacques Touchon, *Montpellier University, Montpellier (France)*, Bruno Vellas, *Gerontopole, Toulouse University, Toulouse (France)*, Mike Weiner, *UCSF, San Francisco, CA (USA)*
- 4.30 p.m **KEYNOTE 1**
Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities
Suzanne Craft, *Wake Forest University School of Medicine, Winston-Salem, NC (USA)*
- 4.50 p.m **Lecanemab Phase 3 Topline Results**
- 6.30 p.m **CTAD Welcome Reception with the support of the Alzheimer's Association** 
- 7.30 p.m **End of the Conference Day**



● Wednesday, NOVEMBER 30



9.00 a.m

KEYNOTE 2

Precision Prevention of Dementia and Alzheimer's Disease: Advancing Multidomain Interventions

Miia Kivipelto, Karolinska Institutet, Center for Alzheimer Research, Karolinska University Hospital, Stockholm (Sweden)

9.20 a.m

SYMPOSIUM 1

CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials

Chair: Kaj Blennow, University of Gothenburg, Gothenburg (Sweden)

Presentation 1: Relationship between blood plasma and CSF measures of A β 42/40, tau, and NfL species for tracking drug effects in clinical trials of Alzheimer's disease

Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (USA)

Presentation 2: Consideration and use of AT(N) blood-based biomarkers for community screening

Michelle M. Mielke, Wake Forest University School of Medicine, Winston-Salem, NC (USA)

Presentation 3: Implementation of plasma biomarkers into clinical practice and trials

Oskar Hansson, Lund University, Lund (Sweden)

10.00 a.m

Coffee break and poster session



10.30 a.m

LATE BREAKING ORAL COMMUNICATIONS

10.30 a.m

LB1 - Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials

Keith Johnson¹, Aaron Schultz¹, Robert Rissman², Oliver Langford², Emma Thibault¹, Matthew Meyer³, Kristopher Kirmess³, Michael Irizarry⁴, Jin Zhou⁴, Michael Donohue², Rema Raman², Paul Aisen², Reisa Sperling^{5,1}, Ahead 3-45 Study Team⁶

¹Massachusetts General Hospital - Boston (United States), ²University of Southern California - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴Eisai - Nutley (United States), ⁵Brigham and Women's Hospital - Boston (United States), ⁶ACTC - Many Sites (United States)

10.45 a.m

LB2 - Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD

Robert Rissman^{1,2}, Oliver Langford², Michael Donohue², Rema Raman², Sara Abdel-Latif², Matthew Meyer³, Kristopher Kirmess³, Joel Braunstein³, Michael Irizarry⁴, Keith Johnson⁵, Paul Aisen², Reisa Sperling⁶, Team Ahead 3-45 Study⁷

¹UC San Diego - La Jolla, Ca (United States), ²University of Southern California - San Diego, Ca (United States), ³C2N Diagnostics - St. Louis, Mo (United States), ⁴Eisai - Indianapolis, In (United States), ⁵Massachusetts General Hospital, Harvard University - Boston, Ma (United States), ⁶Brigham and Woman's Hospital, Harvard - Boston, Ma (United States), ⁷ACTC - San Diego, Ca (United States)

11.00 a.m

ORAL COMMUNICATIONS

11.00 a.m

OC1 - ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimer's Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity

Johannes Streffer^{1,2}, Julien Mermoud¹, Olivier Sol¹, Marija Vukicevic¹, Emma Fiorini¹, Eva Gollwitzer¹, Valérie Hliva¹, David Hickman¹, Julian Gray¹, Piergiorgio Donati¹, Maria Pilar Lopez Deber¹, Julien Rongère¹, Andrea Pfeifer¹, Marie Kosco-Vilbois¹, Philip Scheltens³

¹AC Immune SA - Lausanne (Switzerland), ²University of Antwerp - Antwerp (Belgium), ³VUMC - Amsterdam (The Netherlands)

11.15 a.m

OC2 - Results of a Phase 2/3 Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study to Evaluate the Efficacy and Safety of 12 Week Treatment with the Phosphodiesterase 9 (PDE9) inhibitor Irseontrine (E2027) in Subjects With Dementia With Lewy Bodies

Michael Irizarry¹, Robert Lai², Steven Hersch¹, Kate Pinner², Shobha Dhadda¹, Lynn Kramer¹

¹Eisai Inc. - Nutley (United States), ²Eisai Ltd. - Hattfield (United Kingdom)

● Wednesday, NOVEMBER 30

- 11.30 a.m. **OC3 - An Update on Interim Data for the First Tau Aggregation Inhibitor – Hydromethylthionine mesylate (HMTM)**
Bjoern Schelter^{1,2}
¹TauRx Therapeutics Ltd - Aberdeen (United Kingdom), ²University of Aberdeen - Aberdeen (United Kingdom)
- 11.45 a.m. **OC4 - Janssen Simoa Plasma p217+tau assay as a precision prescreening tool in Autonomy Ph2 anti-tau monoclonal Ab trial in early Alzheimer's Disease**
Gallen Triana-Baltzer¹, Ziad Saad ¹, Setareh Moughadam ¹, Randy Slemmon ¹, Mary Quiceno ¹, David Henley ¹, Hartmuth Kolb ¹
¹Janssen Research & Development - San Diego (United States)
- 12.00 p.m. **OC5 - Long term and economic outcomes for mirtazapine and carbamazepine versus placebo: new data from the SYMBAD RCT**
Sube Banerjee On Behalf Of The Symbad Group ¹
¹University Of Plymouth - Plymouth (United Kingdom)
- 12.15 p.m. Lunch break and poster session
- 1.20 p.m. **SYMPOSIUM 2**
Decentralization Approaches for Clinical Trials on Alzheimer's Disease
Chair: Holly Massett, National Institute on Aging – Bethesda, MD (United States)

Presentation 1: Remote assessments in a follow-on study from TRAILBLAZER-ALZ
Jessica Langbaum, Banner Alzheimer's Institute - Phoenix, AZ (United States)

Presentation 2: Effects of supervision on cognitive and functional assessment outcomes
Paul Maruff, CogState - Melbourne (Australia)

Presentation 3: Decentralization approaches in TRAILBLAZER-ALZ 3
Roy Yaari, Eli Lilly and Company - Indianapolis, IN (United States)

Presentation 4: Investigator experience in a decentralized clinical trial on Alzheimer's Disease
Ralph Lee, Irvine Clinical Research - Irvine, CA (United States)
- 2.00 p.m. **ORAL COMMUNICATIONS' FOCUS SESSION: New Insights for Amyloid and Tau PET Imaging**
- 2.00 p.m. **OC6 - Combination of regional flortaucipir quantification and event-based modeling in clinical trial analyses**
Ixavier Higgins¹, Amanda Morris ¹, John Sims ¹, Mark Mintun ¹, Sergey Shcherbinin ¹
¹Eli Lilly and Company - Indianapolis (United States)
- 2.10 p.m. **OC7 - Longitudinal Tau PET increase is highest in brain regions with strongest functional connectivity to regions with most NFT at Baseline: An independent validation**
Ziad S. Saad¹, Ritobrato Datta ¹, Christopher Rowe ², Hartmuth C. Kolb ¹
¹Janssen R&D, Johnson & Johnson - San Diego (United States), ²Austin Health and University of Melbourne - Melbourne (Australia)
- 2.20 p.m. **OC8 - Individualised tau-PET measures might be superior to group level measures when determining change in tau deposition over time in Alzheimer's disease**
Antoine Leuzy¹, Alexa Pichet-Binette ¹, Jacob W. Vogel ², Gregory Klein ³, Edilio Borroni ³, Matteo Tonietto ³, Olof Strandberg ¹, Niklas Mattsson-Carlgrén ¹, Sebastian Palmqvist ¹, Erik Stomrud ¹, Rik Ossenkoppele ¹, Ruben Smith ¹, Oskar Hansson ¹
¹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund (Sweden), ²Penn/CHOP Lifespan Brain Institute, University of Pennsylvania, Philadelphia (United States), ³F. Hoffmann-La Roche Ltd, Basel (Switzerland)

● Wednesday, NOVEMBER 30



- 2.30 p.m **OC9 - Prevalence and longitudinal clinical outcomes of visually 18F-flortaucipir PET-positive individuals across the Alzheimer's disease spectrum**
Alexis Moscoso¹, Fiona Heeman¹, Valle Camacho², Martijn Van Essen³, Michel J Grothe⁴, Li Lin⁵, Ismini Mainta⁶, Federica Ribaldi⁷, Michael D Devous⁸, Michael J Pontecorvo⁸, Giovanni B Frisoni⁷, Valentina Garibotto⁷, Michael Schöll¹
¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), ²Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. - Barcelona (Spain), ³Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. - Gothenburg (Sweden), ⁴Movement Disorders Group, Institute of Biomedicine of Seville-IBiS, Seville, Spain. - Sevilla (Spain), ⁵Department of radiology, the third affiliated hospital of sun yat-sen university. - Guangzhou (China), ⁶Division of Nuclear Medicine, Geneva University Hospitals, Geneva, Switzerland. - Genève (Switzerland), ⁷Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland - Genève (Switzerland), ⁸Avid Radiopharmaceuticals, Philadelphia, PA, USA - Philadelphia (United States)
- 2.40 p.m **OC10 - Concordance of Visual and Quantitative Analysis for Amyloid PET Imaging With Three 18F Tracers in the CHARIOT-PRO Substudy**
Gerald Novak¹, Ziad Saad², David Scott³, Chi Udeh-Momoh⁴, Luc Bracoud⁵, Craig Ritchie⁶, Lefkos Middleton⁷
¹Janssen R&D - Titusville, Nj (United States), ²Janssen R&D - La Jolla, Ca (United States), ³Clario (formerly Bioclinica) - San Mateo, Ca (United States), ⁴Imperial College - London (United Kingdom), ⁵Clario (formerly Bioclinica) - Lyon (France), ⁶University of edinburgh - Edinburgh (United Kingdom), ⁷Imperial College - Edinburgh (United Kingdom)
- 2.50 p.m **OC11 - Amyloid IQ quantification strongly agrees with both histopathology and visual reads across multiple amyloid tracers**
Alex Whittington¹, Santiago Bullich², Lily Porat¹, Roger Gunn¹
¹Invicro - London (United Kingdom), ²Life Molecular Imaging - Berlin (Germany)
- 3.00 p.m **LATE BREAKING ORAL COMMUNICATIONS**
- 3.00 p.m **LB3 - TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease**
Stephen Salloway¹, Elly Lee², Michelle Papka³, Andrew Pain⁴, Ena Oru⁴, Margaret B. Ferguson⁴, Hong Wang⁴, Michael Case⁴, Ming Lu⁴, Emily C. Collins⁴, Dawn Brooks⁴, John Sims⁴
¹Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital - Providence (United States), ²Irvine Clinical Research - Irvine (United States), ³The Cognitive and Research Center of New Jersey LLC - Springfield (United States), ⁴Eli Lilly and Company - Indianapolis (United States)
- 3.15 p.m **LB4 - CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer's disease**
Kanta Horie^{1,2}, Gemma Salvadó³, Nicolas Barthélemy¹, Yan Li¹, Benjamin Saef¹, Charlie Chen¹, Hong Jiang¹, Brian Gordon¹, Tammie Benzinger¹, David Holtzman¹, Suzanne Schindler¹, Oskar Hansson^{3,4}, Randall Bateman¹
¹Washington University School of Medicine - St. Louis (United States), ²Eisai Inc. - Nutley (United States), ³Lund University - Lund (Sweden), ⁴Skåne University Hospital - Malmö (Sweden)
- 3.30 p.m **LB5 - Top-line Results from the 2-Year Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT)**
Kristine Yaffe¹, Eric Vittinghoff¹, Sascha Dublin², Carrie Peltz¹, Lynn Fleckenstein², Dori Rosenberg², Deborah Barnes¹, Benjamin Balderson², Eric Larson³
¹University of California, San Francisco - San Francisco, Ca (United States), ²Kaiser Permanente Washington Health Research Institute - Seattle, Wa (United States), ³University of Washington - Seattle, Wa (United States)
- 3.45 p.m Coffee break and poster session 
- 4.15 p.m **Topline Results of Phase III GRADUATE I & II Confirmatory Trials with Subcutaneous Gantenerumab**
- 5.15 p.m **End of the Conference Day**

Thursday, DECEMBER 1

- 9.00 a.m** **KEYNOTE 3**
The Current and Future State of AD plasma biomarkers
Kaj Blennow, *University of Gothenburg, and Sahlgrenska University Hospital - Gothenburg (Sweden)*
- 9.20 a.m** **Anti Amyloid Phase 3 results: A CTAD open discussion**
Maria Carrillo¹, David Knopman², Lefkos Middleton³, Ron Petersen²
¹ Alzheimer's Association - Chicago, IL (United States), ² Mayo Clinic - Rochester, MN (United States), ³ Imperial College - London (United Kingdom)
- 9.50 a.m** **ORAL COMMUNICATIONS' FOCUS SESSION: Beyond Amyloid and Tau: Emerging solutions**
Chair: **Howard Fillit**, *Alzheimer's Drug Discovery Foundation, New York, NY (USA)*
- 9.55 a.m** **OC12 - Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?**
Carl Cotman¹, Howard Feldman², Andrea Lacroix², Aladdin Shadyab², Diane Jacobs², David Salmon², Ron Thomas², Shelia Jin², Judy Pa², Jeffrey Katula³, Robert Rissman⁴, James Brewer², Youngkyoo Jung⁵, Jing Zhang², **Laura Baker⁶
*¹UCI (United States), ²UCSD (United States), ³Wake Forest University (United States), ⁴USC (United States), ⁵UC Davis (United States), ⁶Wake Forest University School of Medicine (United States)***
- 10.10 a.m** **OC13 - Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) – Pilot Study Results on Central Nervous System Penetrance and Alzheimer's Disease Biomarkers**
Mitzi Gonzales¹, Valentina Garbarino¹, Tiffany Kautz¹, Ronald Petersen², Tamara Tchkonja², James Kirkland², Suzanne Craft³, Sudha Seshadri¹, Nicolas Musi¹, Miranda Orr³
¹UT Health San Antonio - San Antonio (United States), ²Mayo Clinic - Rochester (United States), ³Wake Forest School Of Medicine - Winston-Salem (United States)
- 10.25 a.m** **OC14 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of T2001 in Alzheimer Patients**
Ronald Van Der Geest¹, Anastasia Lili¹, Oscar Van Loosbroek¹, Andreia Almeida¹, Marlies Oosthoek², Charlotte Teunissen², Sietske Sikkes³, Everard Vijverberg²
¹TreeWay T2001AD BV - Tilburg (Netherlands), ²Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ³Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands)
- 10.40 a.m** **OC15 - Protein Biomarkers in Autosomal Dominant Alzheimer's Disease Cerebrospinal Fluid Identify Early Changes in Brain Glucose Metabolism and the Matrisome**
Shijia Bian¹, E. Kathleen Carter¹, Rafi Haque¹, Caroline Watson¹, Brian Gordon², Lingyan Ping¹, Duc Duong¹, Michael Epstein¹, James Lah¹, Blaine Roberts¹, Anne Fagan², Nicholas Seyfried¹, Allan Levey¹, Erik Johnson¹
¹Emory University - Atlanta (United States), ²Washington University - St. Louis (United States)
- 10.55 a.m** Coffee break and poster session ☕
- 11.20 a.m** **Tackling Agitation in Alzheimer's Dementia: Brexpiprazole phase III trial results**
Presentation: Daniel Lee², Mary Slomkowski², Nanco Hefting³, Dalei Chen², Klaus Larsen³, Eva Kohegyi², Mary Hobart², Jeffrey Cummings⁴
¹Department of Psychiatry and Behavioral Neuroscience at Saint Louis University School of Medicine - St. Louis, Missouri (United States), ²Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton, New Jersey (United States), ³H. Lundbeck A/S - Valby, Copenhagen (Denmark), ⁴Chambers-Grundy Center for Transformative Neuroscience at School of Integrated Health Sciences University of Nevada Las Vegas (UNLV) - Las Vegas, Nevada (United States)
- Panel discussion**

● Thursday,
DECEMBER 1



12.00 p.m

LATE BREAKING ORAL COMMUNICATIONS

12.00 p.m

LB6 - Two-year prognostic utility of plasma p217+tau in the Alzheimer continuum

Azadeh Feizpour^{1,2}, Vincent Doré^{2,3}, James D. Doecke⁴, Ziad S. Saad⁵, Gallen Triana-Baltzer⁵, Natasha Krishnadas^{1,2}, Christopher Fowler¹, Larry Ward¹, Ralph N. Martins^{6,7}, Colin L. Masters¹, Victor L. Villemagne^{2,8}, Jurgen Fripp⁴, Hartmuth C. Kolb⁵, Christopher C. Rowe^{2,1,9}

¹The Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia - Melbourne (Australia), ²Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia - Melbourne (Australia), ³The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia - Melbourne (Australia), ⁴The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia - Brisbane (Australia), ⁵Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA - San Diego (United States), ⁶Edith Cowan University - Perth (Australia), ⁷McCusker Alzheimer's Research Foundation, Nedlands, - Perth (Australia), ⁸Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA - Pittsburgh (United States), ⁹Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia - Melbourne (Australia)

12.15 p.m

LB7 - ALZ-NET: Using Real World Evidence to Define the Future of Alzheimer's Treatment and Care

Maria Carrillo¹, Gil Rabinovici², Michael Rafii³

¹Alzheimer's Association - Chicago (United States), ²Memory and Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco - San Francisco (United States), ³Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California - San Diego (United States)

12.30 p.m

Lunch break and poster session

1.30 p.m

ORAL COMMUNICATIONS

1.30 p.m

OC16 - Leveraging novel technologies to design and implement more patient focused clinical trials

Dave Miller¹ ¹Unlearn.AI - Berkeley (United States)

1.45 p.m

OC17 - Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?

Rik Ossenkoppele¹, Alexa Pichet Binette¹, Colin Groot¹, Reisa Sperling², Colin Masters³, Wiesje Van Der Flier⁴, William Jagust⁵, Petersen Ronald⁶, Clifford Jack⁶, Oskar Hansson¹

¹Lund University - Lund (Sweden), ²MGH - Boston (United States), ³The Florey Institute Of Neuroscience And Mental Health Melbourne Victoria Australia - Parkville (Australia), ⁴Amsterdam University Medical Center - Amsterdam (Netherlands), ⁵UC Berkeley - Berkeley (United States), ⁶Mayo Clinic - Rochester (United States)

2.00 p.m

OC18 - Plasma NT1-tau correlates with age and cognitive decline in two large Down syndrome cohorts

Andrew M. Stern¹, Kathryn L. Van Pelt², Lei Liu¹, Amirah K. Anderson¹, Beth Ostaszewski¹, Dennis J. Selkoe¹, Frederick Schmitt², Elizabeth Head³

¹Ann Romney Center For Neurologic Diseases, Brigham And Women's Hospital, Harvard Medical School - Boston, MA (United States), ²Sanders-Brown Center For Aging, Department Of Neurology, University Of Kentucky - Lexington, KY (United States), ³Department Of Pathology And Laboratory Medicine, University Of California, Irvine - Irvine, CA (United States)

2.15 p.m

OC19 - Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle burden

Gemma Salvadó¹, Rik Ossenkoppele^{1,2}, Nicholas J Ashton^{3,4,5}, Thomas G Beach⁶, Geidy E Serrano⁶, Gwendlyn Kollmorgen⁷, Henrik Zetterberg^{3,8,9,10}, Shorena Janelidze¹, Kaj Blennow³, Oskar Hansson^{1,11}

¹Clinical Memory Research Unit, Department Of Clinical Sciences, Malmö, Lund University - Lund (Sweden), ²Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center - Amsterdam (Netherlands), ³Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), ⁴Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London - London (United Kingdom), ⁵NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation - London (United Kingdom), ⁶Banner Sun Health Research Institute - Sun City (United States), ⁷Roche Diagnostics GmbH - Penzberg (Germany), ⁸Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁹Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), ¹⁰UK Dementia Research Institute at UCL - London (United Kingdom), ¹¹Memory Clinic, Skåne University Hospital - Malmö (Sweden)

Thursday, DECEMBER 1

2.30 p.m

ROUNDTABLE 1

Investments in Innovation: Advancing the Path Forward to New Alzheimer's Treatments

Chair: Niranjan Bose, *Gates Ventures, Seattle, WA (United States)*

Discussants: Howard Fillit, *Alzheimer's Drug Discovery Foundation (ADDF), New York City, NY (United States)*; Laurence Barker, *Partner in the Dementia Discovery Fund (DDF), London (United Kingdom)*; Philip Scheltens, *LSP Dementia Fund at EQT Life, Alzheimer Centre Amsterdam (University Medical Centre Amsterdam, Amsterdam (The Netherlands))*

3.00 p.m

ORAL COMMUNICATIONS

3.00 p.m

OC20 - Systemic inflammation and reduced cerebral A β clearance triggered by pancreatic amylin

Florin Despa¹, Nirmal Verma¹, Edric Winford¹, Peter Nelson¹, Gregory Jicha¹, Larry Goldstein¹, Claire Troakes², Henrik Zetterberg³, John Hardy³, Tammamyn Lashley³

¹University Of Kentucky - Lexington (United States), ²King's College London - London (United Kingdom), ³Dementia Research Institute at UCL - London (United Kingdom)

3.15 p.m

OC21 - Prazosin for Agitation in Alzheimer's Disease: PEACE-AD

Elaine Peskind¹, Murray Raskind², Ronald Thomas³, Gregory Jicha⁴, Neela Patel⁵, Amy Pierce⁶, Sharon Brangman⁷, Mary Sano⁸, Jeffrey Kaye⁶, Miranda Lim⁶, Michael Au-Yeung⁶, Michelle Herman⁹, Gabriel Leger⁹, Karen Messer⁹, Howard Feldman⁹

¹VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC), Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), ²VA Northwest Mental Illness Research, Education and Clinical Center (MIRECC) and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle (United States), ³Departments of Family Medicine and Neurosciences, University of California San Diego - La Jolla (United States), ⁴Department of Neurology, University of Kentucky - Lexington (United States), ⁵Department of Family and Community Medicine, UT Health San Antonio - San Antonio (United States), ⁶Department of Neurology, OHSU School of Medicine - Portland (United States), ⁷Department of Geriatrics, SUNY Upstate Medical University - Syracuse (United States), ⁸Department of Psychiatry, Mount Sinai School of Medicine - New York (United States), ⁹Department of Neurosciences, University of California San Diego - La Jolla (United States)

3.30 p.m

OC22 - Demographic Analysis of Industry Sponsored Alzheimer's Disease Trial Populations in the United States

Stephen Peroutka¹ - ¹PPD, Part Of Thermo Fisher Scientific - Carmel, CA (United States)

3.45 p.m

OC23 - Plasma Biomarker Findings from the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

Eric M. Reiman¹, Francisco Lopera², Silvia Rios-Romenets², Courtney Schiffman³, Derrek Hibar³, Gwendlyn Kollmorgen⁴, Margarita Giraldo², Natalia Acosta², Alejandro Espinosa², Gustavo Villegas², Claudia Muñoz², Laura Serna², Karina Herrera², Yi Su¹, Robert Alexander¹

¹Banner Alzheimer's Institute - Phoenix, Arizona (United States), ²Neurosciences Group of Antioquia, University of Antioquia - Medellín (Colombia), ³Genentech, Inc. - South San Francisco, Ca (United States), ⁴Roche Diagnostics GmbH - Mannheim (Germany)

4.00 p.m

Coffee break and poster session 

4.30 p.m

LATE BREAKING ORAL COMMUNICATIONS

4.30 p.m

LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer's Disease (AD)

Stephen Macfarlane¹, Timo Grimmer², Terence O'Brien³, Edward Hammond⁴, Walter Kaufmann⁴, Emmanuel Fadiran⁴, Christopher Missling⁴

¹Hammoncare - Melbourne (Australia), ²THU Munich - Munich (Germany), ³Monash University, Alfred Health - Melbourne (Australia), ⁴Anavex Life Sciences - New York (United States)

4.45 p.m

LB9 - Higher sensitivity amyloid-PET detection of the earliest focal beta-amyloid accumulation using spatial extent

Michelle E. Farrell¹, Emma G. Thibault¹, J. Alex Becker¹, Julie C. Price¹, Kuang Gong¹, Aaron P. Schultz¹, Michael J Properzi¹, Rachel F Buckley^{1,2}, Heidi I.I. Jacobs¹, Bernard J. Hanseeuw^{1,3}, Reisa A. Sperling^{1,2}, Keith A. Johnson^{1,2}

¹Massachusetts General Hospital - Boston, Ma (United States), ²Brigham & Women's Hospital - Boston, Ma (United States), ³Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Brussels (Belgium)

● Thursday, DECEMBER 1

5.00 p.m

LB10 - Sample size estimates for preclinical AD intervention trials based on Wisconsin Registry for Alzheimer's Prevention Longitudinal PET amyloid, plasma P-tau217, and cognitive assessment data

Rebecca Langhough Kosciak¹, Derek Norton¹, Tobey Betthausen¹, Lianlian Du¹, Erin Jonaitis¹, Karly Cody¹, Bruce Hermann¹, Kimberly Mueller¹, Rick Chappell¹, Bradley Christian¹, Shorena Janelidze¹, Niklas Mattsson-Carlgen¹, Oskar Hansson¹, Sterling Johnson¹

¹University of Wisconsin SMPH - Madison (United States)

5.15 p.m

LB11 - Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer's Disease: Results From the PEGASUS Trial

Steven E. Arnold^{1,2}, Newman Knowlton³, Victoria J. Williams⁴, Jeffrey M. Burns⁵, Monica Crane⁶, Alison J. Mcmanus¹, Sanjeev N. Vaishnavi⁷, Zoe Arvanitakis⁸, Judith Neugroschl⁹, Karen Bell¹⁰, Bianca A. Trombetta¹, Becky C. Carlyle¹¹, Pia Kivisäkk^{12,2}, Rudolph E. Tanzi^{13,14}, Kent Leslie^{15,16}

¹Department of Neurology, Massachusetts General Hospital, Boston, MA, USA - Boston (United States), ²Harvard Medical School, Boston, MA, USA - Boston (United States), ³Pentara Corporation, Millcreek, UT, USA - Millcreek (United States), ⁴Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA - Madison (United States), ⁵University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA - Kansas City (United States), ⁶Genesis Neuroscience Clinic, Knoxville, TN, USA - Knoxville (United States), ⁷Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA - Philadelphia (United States), ⁸Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA - Chicago (United States), ⁹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA - New York (United States), ¹⁰Department of Neurology, Columbia University, New York, NY, USA - New York (United States), ¹¹Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, England, United Kingdom - England (United Kingdom), ¹²Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; ²Harvard Medical School, Boston, MA, USA - Boston (United States), ¹³Harvard Medical School, Boston, MA, USA - Boston (United Kingdom), ¹⁴Department of Neurology, Genetics and Aging Research Unit, McCance Center for Brain Health, Massachusetts General Hospital, Harvard University, Boston, MA, USA - Boston (United States), ¹⁵Amylyx Pharmaceuticals, Inc., Cambridge, MA, USA - Cambridge (United States), ¹⁶Present address: Division of Biology and Biological Engineering Graduate Program, California Institute of Technology, Pasadena, CA, USA - Pasadena (United States)

5.30 p.m

End of the Conference Day

● Friday, DECEMBER 2

- 9.00 a.m. **KEYNOTE 4**
Therapeutic Reversal of Amyloid and Tau Pathology in Alzheimer's Disease
Roger Nitsch, *Neurimmune, Schlieren (Switzerland)*
- 9.20 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 9.20 a.m. **LB12 - Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients With Symptoms of Cognitive Impairment**
Joel Braunstein¹, Mark Monane¹, Kim Johnson², B. Joy Snider³, Raymond Scott⁴, Jonathan Drake⁵, Daniel Jacobs⁶, Julia Ortega¹, Joni Henderson¹, Tim West¹
¹C2N Diagnostics - St Louis (United States), ²Duke University - Durham (United States), ³Washington University - St Louis (United States), ⁴Georgetown University - Washington (United States), ⁵Lifespan - Providence (United States), ⁶Neurological Services of Orlando - Orlando (United States)
- 9.35 a.m. **LB13 - Phase 1 pharmacokinetic and CNS target engagement properties of the orally administered O-GlcNAcase inhibitor ASN51 in humans**
Ryan Schubert¹, Rolf Pokorny¹, Bruno Permanne¹, Pearl Fang¹, Vanessa Teachout¹, Maud Nény¹, Solenne Ousson¹, Jennifer Hantson¹, Astrid Sand¹, Ruhi Ahmed¹, Manfred Schneider¹, Jean-Francois Stallaert¹, Anna Quattropani¹, Eric Yuen¹, Dirk Beher¹
¹Asceneuron, Lausanne (Switzerland)
- 9.50 a.m. **LB14 - Analysis of 15 software pipelines for validation of [18F]florbetaben PET quantitation**
Aleksandar Jovalekic¹, Nuria Roe-Vellve¹, Norman Koglin¹, Mariana Lagos Quintana¹, Aaron Nelson², Markus Diemling³, Johan Lilja³, Juan Pablo Gomez Gonzalez⁴, Vincent Dore⁵, Pierrick Bourgeat⁵, Alex Whittington⁶, Roger Gunn⁶, Andrew Stephens¹, Santiago Bullich¹
¹Life Molecular Imaging - Berlin (Germany), ²MIM Software - Cleveland (United States), ³Hermes Medical Solutions - Stockholm (Sweden), ⁴QuBiotech - A Coruna (Spain), ⁵CSIRO - Brisbane (Australia), ⁶Invicro - London (United Kingdom)
- 10.05 a.m. **LB15 - Results from a clinical Study of an Anti-Galectin-3 Monoclonal antibody in Patients with Moderate to Severe Alzheimer's Disease**
Dongxu Sun¹, George Haig¹, Suhail Rasool¹
¹Truebinding Inc - Foster City (United States)
- 10.20 a.m. Coffee break and poster session 
- 10.45 a.m. **ROUNDTABLE 2**
The Alzheimer's disease Patient Pathway from a sex and gender lens
Chair: Frances Catherine Quevenco^{1,2}
Discussants: Maria Carmela Tartaglia³, Heather Snyder⁴, Phyllis Ferrell⁵, Pernille Poulsen⁶, Antonella Santucciono Chadha^{7,2}
¹Roche (Switzerland), ²Women's Brain Project (Switzerland), ³University Of Toronto (Canada), ⁴Alzheimer's Association (United States), ⁵Eli Lilly (United States), ⁶Novo Nordisk (Denmark), ⁷Altoida (United States)
- 11.15 a.m. **ORAL COMMUNICATIONS' FOCUS SESSION: Interim or preliminary data and study design**
- 11.15 a.m. **OC24 - Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias**
Kaya Jordan¹, Kennedy Mahdavi^{1,2}, Jonathan Haroon¹, Elisabeth Rindner¹, Margaret Zielinski¹, Victoria Venkatraman^{1,2}, Sergio Becerra², Dayan Goodenowe³, Clarence Ahlem⁴, Christopher Reading⁴, Joseph Palumbo⁴, Bijan Pourat⁵, Sheldon Jordan^{1,2}
¹The Regenesys Project - Santa Monica (United States), ²Synaptec Network - Santa Monica (United States), ³Prodrome Sciences USA LLC - Temecula (United States), ⁴Biovie Inc. - Carson City (United States), ⁵Pourat MD - Beverly Hills (United States)

● Friday, DECEMBER 2



- 11.25 a.m **OC25 - HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer's disease with AGB101: Baseline Tau and MRI imaging characteristics**
Richard Mohs¹, Sharon Rosenzweig-Lipson¹, Arnold Bakker², Elizabeth Chang², Nisha Rani², Russell Barton¹, Michela Gallagher^{1,2}
¹AgeneBio, Inc - Baltimore (United States), ²Johns Hopkins University - Baltimore (United States)
- 11.35 a.m **OC26 - Design of the ABCA1 agonist CS6253 Phase 1 SAD and MAD study in male and female, APOE4 and non-APOE4 carriers to assess safety, PK and biomarker efficacy**
Jan Johansson¹, Hussein Yassine², Danny Michaelson³, Henrik Zetterberg⁴, Jeffrey Cummings⁵, Bengt Winblad⁶
¹Artery Therapeutics, Inc. - San Ramon (United States), ²USC - Los Angeles (United States), ³Tel Aviv University - Tel Aviv (Israel), ⁴U of Gothenburg - Gothenburg (Sweden), ⁵U Nevada Las Vegas - Las Vegas (United States), ⁶Karolinska Insitute - Stockholm (Sweden)
- 11.45 a.m **OC27 - Significant Effects of Oral ALZ-801 on Plasma Biomarkers of Alzheimer's Disease: 12-Month Interim Analysis of Phase 2 Biomarker Study in APOE4 Carriers with Early AD**
Susan Abushakra¹, John Hey¹, Kaj Blennow², Philip Scheltens³, Jakub Hort⁴, Katerina Sheardova⁵, Niels Prins⁶, Sterre Rutgers⁶, Paul Dautzenberg⁷, Ladislav Pazdera⁸, Patrick Kessler¹, Aidan Power¹, Martin Tolar¹
¹Alzheon Inc. - Framingham, Ma (United States), ²Gothenburg University, Institute of Neuroscience & Physiology - Molndal (Sweden), ³Amsterdam University Medical Center - Amsterdam (Netherlands), ⁴Charles University Dept. of Neurology - Prague (Czech Republic), ⁵St. Anne University Hospital & International Clinical Research Center - Brno (Czech Republic), ⁶Brain Research Center - Amsterdam (Netherlands), ⁷Brain Research Center - Den Bosch (Netherlands), ⁸Vestra Research Clinic - Rychnov Nad Kněžnou (Czech Republic)
- 11.55 a.m **OC28 - Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease**
Nicola Spotorno¹, Olof Strandberg¹, Geraline Vis^{2,3}, Erik Stomrud¹, Markus Nilsson^{2,4}, Oskar Hansson¹
¹Clinical Memory Research Unit, Department Of Clinical Sciences, Lund University - Lund (Sweden), ²Diagnostic Radiology, Institution For Clinical Sciences, Lund University - Lund (Sweden), ³Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁴Memory Clinic, Skåne University Hospital - Malmö (Sweden)
- 12.05 p.m Lunch break and poster sessions
- 1.05 p.m **ORAL COMMUNICATIONS**
- 1.05 p.m **OC29 - A brief, automated speech-based screener for mild cognitive impairment to support online recruitment at scale**
Caroline Skirrow¹, Jack Weston¹, Marton Meszaros¹, Udeepa Meepegama¹, Emil Fristed¹
¹Novoic - London (United Kingdom)
- 1.20 p.m **OC30 - Aβ-structure as Precise Risk Plasma Biomarker for Future Conversion to Alzheimer's Disease 17 Years in Advance**
Klaus Gerwert^{1,2}
¹Ruhr-University Bochum - Bochum (Germany), ²Center for Protein Diagnostics (ProDi) - Bochum (Germany)
- 1.35 p.m **ORAL COMMUNICATIONS' FOCUS SESSION: Clinical Trials Phase 1 Results**
- 1.35 p.m **OC31 - NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease**
Daniel Mikol¹, Judy Toews¹, Martin Farlow², Bruce Lamb², George Perry³, Reisa Sperling⁴, Michael Weiner⁵, Henrik Zetterberg⁶, Jeffrey Cummings⁷
¹Nervgen - Vancouver (Canada), ²Indiana University School Of Medicine - Indianapolis (United States), ³University Of Texas, San Antonio - San Antonio (United States), ⁴Harvard Medical School - Cambridge (United States), ⁵University Of California, San Francisco - San Francisco (United States), ⁶University Of Gothenburg - Gothenburg (Sweden), ⁷University Of Nevada, Las Vegas - Las Vegas (United States)

● Friday, DECEMBER 2

- 1.45 p.m **OC32 – Introduction to the Veri-T trial: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Verdiperstat in Patients with svPPA Due to FTLD-TDP**
Peter Ljubenkov¹, Adam Staffaroni¹, Lawren Vandevrede¹, Julio Rojas-Martinez¹, Mary Koestler¹, Anton Porsteinsson², Maria B. Pascual³, Joseph Masdeu³, Ian Grant⁴, David Irwin⁵, David Knopman⁶, Robert Bowser⁷, Murray Grossman⁵, Irfan Qureshi⁸, Adam Boxer¹
¹UCSF Memory and Aging Center - San Francisco (United States), ²University of Rochester - Rochester (United States), ³Houston Methodist - Houston (United States), ⁴Northwestern University - Chicago (United States), ⁵University of Pennsylvania - Philadelphia (United States), ⁶Mayo Clinic Rochester - Rochester (United States), ⁷Barrow Neurological Institute - Phoenix (United States), ⁸Biohaven Pharmaceuticals - New Haven (United States)
- 1.55 p.m **OC33 – A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer’s Disease – Interim Data**
Michael Kaplitt¹, Philip Leopold², Evan Noch³, Jana Ivanidze⁴, Levi Chazen⁴, Ronald Crystal², Stephen Kaminsky², Haley Bowe², Mei Wang², Douglas Ballon⁴, Jonathan Dyke⁴, Dolan Sondhi², Sam Gandy⁵, Gina Giannantoni-Ibelli⁶, Jay Barth⁶
¹Department of Neurological Surgery, Weill Cornell Medical College - New York (United States), ²Department of Genetic Medicine, Weill Cornell Medical College - New York (United States), ³Department of Neurology, Weill Cornell Medical College - New York (United States), ⁴Department of Radiology, Weill Cornell Medical College - New York (United States), ⁵Departments of Neurology and Psychiatry, Icahn School of Medicine at Mt Sinai - New York (United States), ⁶LEXEO Therapeutics, Inc. - New York (United States)
- 2.05 p.m **ORAL COMMUNICATIONS**
- 2.05 p.m **OC34 – Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample**
Chris Edgar¹, Rebecca Amariglio², Jordan Barbone³, Julie Chandler⁴, Stephen Coons⁵, Michael Donohue⁶, William Lenderking⁷, Reisa Sperling⁸
¹Cogstate - London (United Kingdom), ²Departments of Neurology, Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³Cogstate - New Haven (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Clinical Outcome Assessment Program, Critical Path Institute - Tucson (United States), ⁶Alzheimer’s Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁷Patient-centered Research, Evidera - Bethesda (United States), ⁸Department of Neurology, Brigham and Women’s Hospital - Boston (United States)
- 2.20 p.m **OC35 – APOE-Targeted Epigenome Therapy for Alzheimer’s Disease**
Boris Kantor^{1,2}, Ornit Chiba-Falek^{1,3}
¹Duke University - Durham (United States), ²CLAIRGene LLC - Durham (United States), ³CLAIRGene - Durham (United States)
- 2.35 p.m **OC36 – Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance**
Alexa Pichet Binette¹, Shorena Janelidze¹, Nicholas Cullen¹, Jeffrey L. Dage², Randall J. Bateman³, Henrik Zetterberg^{4,5}, Kaj Blennow⁴, Erik Stomrud¹, Niklas Mattsson-Carlgrén¹, Oskar Hansson¹
¹Clinical Memory Research Unit, Faculty Of Medicine, Lund University - Lund (Sweden), ²Department Of Neurology, Indiana University School Of Medicine - Indianapolis (United States), ³Department Of Neurology, Washington University School Of Medicine - St. Louis (United States), ⁴Department Of Psychiatry And Neurochemistry, The Sahlgrenska Academy, University Of Gothenburg - Gothenburg (Sweden), ⁵UK Dementia Research Institute, University College London - London (United Kingdom)
- 2.50 p.m **OC37 – Aducanumab and lecanemab label insoluble, fibrillar, diffusible Aβ aggregates in aqueous extracts of human Alzheimer disease brain**
Andrew M. Stern¹, Angela L. Meunier¹, Wen Liu¹, Maria Ericsson², Dennis J. Selkoe²
¹Ann Romney Center For Neurologic Diseases, Brigham And Women’s Hospital, Harvard Medical School - Boston (United States), ²Harvard Medical School Electron Microscopy Core - Boston (United States)
- 3.05 p.m Coffee break and poster session 

● Friday, DECEMBER 2



3.35 p.m

LATE BREAKING ORAL COMMUNICATION

3.35 p.m

LB16 - Phase 1 Preventive Adjuvanted Tau Vaccine, AV-1980R

Lon Schneider¹, Anahit Ghichikyan², Robert Alexander³, Henrik Zetterberg³, Eric Reiman³, Duygu Tosun⁴, Michael Agadjanyan²
¹USC - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴University of California San Francisco - San Francisco (United States)

3.50 p.m

ORAL COMMUNICATIONS

3.50 p.m

OC38 - A multimodal clinical and lifestyle intervention induces multiomic systemic effects and improves cognitive outcomes in Alzheimer's disease

Jared C. Roach¹, Lance E. Edens¹, Sophiya Rajbhandari¹, Junko Hara², Jennifer Bramen^{3,4}, Molly K. Rapozo⁵, Cory Funk¹, William R. Shankle^{6,7,2,8}, Leroy Hood¹
¹Institute For Systems Biology - Seattle, Washington (United States), ²Pickup Family Neurosciences Institute, Hoag Memorial Hospital Presbyterian - Newport Beach, California (United States), ³Pacific Brain Health Center, Pacific Neuroscience Institute - Santa Monica, California (United States), ⁴Department of Translational Neurosciences and Neurotherapeutics, Saint John's Cancer Institute - Santa Monica, California (United States), ⁵Providence St. Joseph Health - Renton, Washington (United States), ⁶Shankle Clinic - Newport Beach, California (United States), ⁷Department of Cognitive Sciences, University of California - Irvine, California (United States), ⁸EMBIC Corporation - Newport Beach, California (United States)

4.05 p.m

OC39 - Advantages of next generation SupraAntigen® platform liposomal vaccines to immunize against pathological targets of Alzheimer's disease

Marija Vukicevic¹, Emma Fiorini¹, David Hickman¹, Raket Carpintero², Marcela Rincon², Maria Pilar Lopez-Deber², Maxime Ayer², Stefanie Siegert², Chiara Babolin², Eva Gollwitzer², Saskia Delpretti-Anex², Piergiorgio Donati², Johannes Streffer^{2,3}, Andrea Pfeifer², Marie Kosco-Vilbois²
¹Ac Immune SA - Lausanne (Switzerland), ²AC Immune SA - Lausanne (Switzerland), ³University of Antwerp - Antwerpen (Belgium)

4.20 p.m

OC40 - U-p53AZ in prognostication of early onset Alzheimer's disease up to 6 years in advance of the clinical diagnosis

Simona Picciarella¹, Leander Van Neste², Christofer Fowler³, Colin Masters³, Jurgen Fripp⁴, James D. Doecke⁴, Chengjie Xiong⁵, Daniela Uberti⁶, Paul Kinnon¹
¹Diadem SpA - Brescia (Italy), ²Halixo BV - Hoegaarden (Belgium), ³The Florey Institute of Neuroscience and Mental Health - Parkville (Australia), ⁴The Australian e-Health Research Centre, CSIRO - Herston (Australia), ⁵Washington University School of Medicine, Division of Biostatistics - St. Louis (United States), ⁶Department of Molecular and Translational Medicine, University of Brescia - Brescia (Italy)

4.35 p.m

OC41 - iWHELD: An RCT of a Novel Digital Non-Pharmacological Intervention to Improve Quality of Life and Reduce Antipsychotics in 741 People Living in Nursing Homes During the COVID-19 Pandemic

Clive Ballard¹, Joanne Mcdermid¹, Adrienne Sweetnam¹
¹University of Exeter - Exeter (United Kingdom)

4.50 p.m

OC42 - Making digital measures fit-for-purpose in Alzheimer's trials

Francesca Cormack¹, Jennifer Sorinas², Claire Meunier³
¹Cambridge Cognition - Cambridge (United Kingdom), ²Novartis - Basel (Switzerland), ³DiMe - San Francisco (United States)

5.05 p.m

End of the Conference Day



CTAD 2022 VENUE

CTAD 2022 will be held at the **Hilton Union Square**

333 O'Farrell Street

San Francisco, CA 94102, USA

The hotel is steps from the Curran and ACT theaters and just two blocks from Union Square and Westfield shopping center. The Powell Street cable car turnaround, San Francisco Museum of Modern Art, and Moscone Convention Center are within a mile. Enjoy panoramic views from our skybar, the city's highest.

CTAD has negotiated special rates for its attendees at 296US\$ inclusive of breakfast and exclusive of taxes.

Book at www.ctad-alzheimer.com



Clinical Trials on Alzheimer's Disease

Mark your agenda!

LATE CALL FOR ABSTRACTS
September 15-30

Graphic Design: Melanie Vaisselle - @Tlenny

Follow us on social media!



[@CTADConference](https://twitter.com/CTADConference)
[#CTAD22](https://twitter.com/CTADConference)



[CTAD Conference](https://www.facebook.com/CTADConference)



[CTAD Alzheimer](https://www.linkedin.com/company/CTADAlzheimer)

Email: ctad@ant-congres.com
www.ctad-alzheimer.com